Spyre Therapeutics (SYRE)

Spyre Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

12.5M

Short interest

settlement 2026-10-15

7.3

Days to cover

-1.6 days vs prior

66.5%

Short share of volume

2026-10-28

788

Fails to deliver

settlement 2026-09-24

Tue 3 Nov

Next earnings

estimated date

-$16.9M

Insider flow, 90 days

0 buys, 42 sells

As of 2026-10-28.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in SYRE is 12,505,491 shares, up 376,048 shares over the last month. Over the last 48 readings it ranged from 8,040,536 shares (15 November 2024) to 14,459,688 shares (30 September 2025). At the reported average volume of 1.7M shares a day that is 7.3 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/syre" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	12,505,491	-2.6%	1,704,147	7.34
2026-09-30	12,844,608	+5.9%	1,444,056	8.89
2026-09-15	12,129,443	+2.3%	1,047,388	11.58
2026-08-31	11,859,975	+0.9%	1,223,666	9.69
2026-08-14	11,755,434	-3.2%	736,817	15.95
2026-07-31	12,143,879	-2.9%	898,547	13.52
2026-07-15	12,508,710	-8.3%	1,385,250	9.03
2026-06-30	13,640,183	+8.1%	2,455,257	5.56
2026-06-15	12,616,535	-0.1%	1,165,484	10.83
2026-05-29	12,627,576	+1.7%	816,178	15.47
2026-05-15	12,417,051	+1.6%	1,189,799	10.44
2026-04-30	12,221,682	+4.7%	1,217,137	10.04
2026-04-15	11,672,747	+11.8%	1,587,932	7.35
2026-03-31	10,435,737	+4.4%	909,125	11.48
2026-03-13	9,997,086	+0.1%	714,840	13.99
2026-02-27	9,985,198	+1.2%	803,682	12.42
2026-02-13	9,862,924	-1.2%	663,160	14.87
2026-01-30	9,980,496	-0.9%	491,985	20.29
2026-01-15	10,069,741	-13.5%	724,793	13.89
2025-12-31	11,636,998	-1.5%	827,619	14.06
2025-12-15	11,818,159	+5.9%	852,169	13.87
2025-11-28	11,157,711	-10.5%	610,966	18.26
2025-11-14	12,464,842	+0.5%	618,472	20.15
2025-10-31	12,407,305	-7.3%	1,043,667	11.89
2025-10-15	13,390,470	-7.4%	1,456,858	9.19
2025-09-30	14,459,688	+4.9%	795,084	18.19
2025-09-15	13,780,763	-2.2%	483,003	28.53
2025-08-29	14,087,087	+6.8%	479,985	29.35
2025-08-15	13,187,699	+2.4%	432,371	30.50
2025-07-31	12,879,446	-5.3%	551,685	23.35
2025-07-15	13,602,876	+0.9%	588,212	23.13
2025-06-30	13,486,500	+7.1%	795,568	16.95
2025-06-13	12,592,074	+4.2%	461,502	27.28
2025-05-30	12,090,208	-1.7%	364,019	33.21
2025-05-15	12,296,733	-2.0%	592,668	20.75
2025-04-30	12,553,112	+6.8%	587,061	21.38
2025-04-15	11,749,883	+3.4%	1,020,047	11.52
2025-03-31	11,358,696	+5.5%	645,117	17.61
2025-03-14	10,767,640	+7.4%	669,446	16.08
2025-02-28	10,022,703	+1.0%	623,342	16.08
2025-02-14	9,923,952	-3.0%	581,650	17.06
2025-01-31	10,235,934	+2.3%	611,039	16.75
2025-01-15	10,003,304	+0.6%	554,067	18.05
2024-12-31	9,940,874	+3.3%	499,939	19.88
2024-12-13	9,620,365	+8.6%	488,942	19.68
2024-11-29	8,859,758	+10.2%	925,857	9.57
2024-11-15	8,040,536	-2.5%	542,148	14.83
2024-10-31	8,250,593	-1.9%	359,668	22.94

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 28 October 2026, the short share of SYRE volume is 66.5%, up 6.5 points over the last five sessions. Over the last 30 readings it ranged from 25.8% (24 September 2026) to 83.2% (16 October 2026). The latest reading is 5.7 points above the 30-session average of 60.8%, on 288K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-10-28	191K	288K	66.5%	0
2026-10-27	269K	435K	61.8%	0
2026-10-26	197K	309K	63.5%	2,718
2026-10-23	151K	186K	81.2%	0
2026-10-22	150K	228K	65.6%	0
2026-10-21	180K	301K	60.0%	3,758
2026-10-20	435K	646K	67.4%	2,800
2026-10-19	348K	535K	65.1%	75
2026-10-16	348K	418K	83.2%	0
2026-10-15	227K	499K	45.4%	0
2026-10-14	323K	626K	51.7%	0
2026-10-13	334K	587K	56.9%	2,217
2026-10-12	231K	313K	73.8%	0
2026-10-09	335K	518K	64.5%	0
2026-10-08	394K	1.0M	39.3%	0
2026-10-07	729K	1.3M	55.9%	11,494
2026-10-06	1.1M	2.1M	52.8%	14,367
2026-10-05	167K	223K	74.9%	0
2026-10-02	312K	423K	73.9%	0
2026-10-01	429K	739K	58.1%	4,000
2026-09-30	547K	783K	69.9%	20,762
2026-09-29	203K	339K	59.8%	0
2026-09-28	211K	370K	57.0%	3,093
2026-09-25	121K	174K	69.7%	0
2026-09-24	262K	1.0M	25.8%	284
2026-09-23	221K	338K	65.4%	0
2026-09-22	165K	298K	55.5%	406
2026-09-21	179K	395K	45.2%	0
2026-09-18	257K	458K	56.1%	0
2026-09-17	276K	481K	57.4%	0

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 24 September 2026, the fails-to-deliver balance in SYRE is 788 shares, down 4,872 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (16 June 2026) to 207,327 shares (22 June 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-09-24	788	$88.17	$69K
2026-09-21	5,660	$90.25	$511K
2026-09-18	27	$92.68	$3K
2026-09-14	9	$90.60	$815
2026-09-10	24,790	$86.93	$2.2M
2026-08-26	4,795	$107.36	$515K
2026-08-17	5,549	$103.63	$575K
2026-08-11	2,448	$105.33	$258K
2026-07-22	961	$102.70	$99K
2026-07-21	4,468	$97.33	$435K
2026-07-20	821	$100.23	$82K
2026-07-17	2,395	$94.12	$225K
2026-07-16	56	$102.07	$6K
2026-07-07	6,039	$88.74	$536K
2026-06-30	6,600	$90.16	$595K
2026-06-29	4,555	$87.89	$400K
2026-06-26	5,392	$88.67	$478K
2026-06-22	207,327	$88.34	$18.3M
2026-06-18	2,977	$87.49	$260K
2026-06-17	74	$83.41	$6K
2026-06-16	3	$83.58	$251
2026-06-15	514	$80.79	$42K
2026-06-11	1,753	$75.08	$132K
2026-06-05	6	$78.48	$471
2026-06-03	73	$69.16	$5K
2026-06-01	13,710	$73.50	$1.0M
2026-05-29	62	$72.11	$4K
2026-05-28	7	$72.51	$508
2026-05-27	219	$73.65	$16K
2026-05-26	219	$74.05	$16K

Insider trades

SEC Form 4, newest first. JSON

Insiders at SYRE reported 42 open-market sells worth $16.9M in the last 90 days and no open-market buys. Latest filing: Turtle Cameron (Chief Executive Officer) on 2026-10-01.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	100	$93.91	$9K	538K
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	5K	$93.37	$466K	538K
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	4K	$92.31	$368K	543K
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$91.49	$241K	547K
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$90.10	$242K	549K
2026-10-01	Turtle Cameron	Chief Executive Officer	Sell	600	$89.14	$53K	552K
2026-10-01	King-Jones Heidy	See Remarks	Sell	3K	$93.46	$243K	3K
2026-10-01	King-Jones Heidy	See Remarks	Sell	2K	$92.70	$195K	5K
2026-10-01	King-Jones Heidy	See Remarks	Sell	7K	$91.35	$660K	8K
2026-10-01	King-Jones Heidy	See Remarks	Sell	17K	$90.35	$1.5M	15K
2026-10-01	King-Jones Heidy	See Remarks	Sell	400	$89.24	$36K	31K
2026-10-01	King-Jones Heidy	See Remarks	Exercise or conversion	29K	$14.50	$420K	32K
2026-10-01	Burrows Scott L	Chief Financial Officer	Sell	229	$93.57	$21K	80K
2026-10-01	Burrows Scott L	Chief Financial Officer	Sell	3K	$92.95	$285K	80K
2026-10-01	Burrows Scott L	Chief Financial Officer	Sell	2K	$91.92	$193K	83K
2026-10-01	Burrows Scott L	Chief Financial Officer	Sell	2K	$90.27	$135K	85K
2026-10-01	Burrows Scott L	Chief Financial Officer	Sell	600	$89.07	$53K	87K
2026-10-01	Burrows Scott L	Chief Financial Officer	Exercise or conversion	8K	$14.50	$109K	87K
2026-09-30	Burrows Scott L	Chief Financial Officer	Sell	18K	$89.89	$1.6M	80K
2026-09-30	Burrows Scott L	Chief Financial Officer	Exercise or conversion	18K	$14.50	$254K	97K
2026-09-02	King-Jones Heidy	See Remarks	Sell	400	$90.00	$36K	3K
2026-09-02	King-Jones Heidy	See Remarks	Exercise or conversion	400	$14.50	$6K	3K
2026-09-02	Burrows Scott L	Chief Financial Officer	Sell	18K	$89.35	$1.6M	80K
2026-09-01	Turtle Cameron	Chief Executive Officer	Sell	400	$89.07	$36K	553K
2026-09-01	Turtle Cameron	Chief Executive Officer	Sell	4K	$88.06	$326K	553K
2026-09-01	Turtle Cameron	Chief Executive Officer	Sell	8K	$87.15	$732K	557K
2026-09-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$86.36	$216K	565K
2026-09-01	King-Jones Heidy	See Remarks	Sell	400	$89.38	$36K	3K
2026-09-01	King-Jones Heidy	See Remarks	Sell	6K	$88.17	$547K	3K
2026-09-01	King-Jones Heidy	See Remarks	Sell	17K	$87.20	$1.4M	9K
2026-09-01	King-Jones Heidy	See Remarks	Sell	5K	$86.40	$419K	26K
2026-09-01	King-Jones Heidy	See Remarks	Exercise or conversion	28K	$14.50	$406K	31K
2026-09-01	Burrows Scott L	Chief Financial Officer	Sell	200	$89.04	$18K	98K
2026-09-01	Burrows Scott L	Chief Financial Officer	Sell	2K	$88.03	$177K	98K
2026-09-01	Burrows Scott L	Chief Financial Officer	Sell	4K	$87.11	$382K	100K
2026-09-01	Burrows Scott L	Chief Financial Officer	Sell	900	$86.25	$78K	105K
2026-09-01	Burrows Scott L	Chief Financial Officer	Exercise or conversion	8K	$14.50	$109K	105K
2026-08-07	Albers Jeffrey W.	Director	Sell	10K	$104.68	$1.0M	9K
2026-08-07	Albers Jeffrey W.	Director	Sell	8K	$104.38	$835K	19K
2026-08-07	Albers Jeffrey W.	Director	Sell	5K	$104.47	$522K	0
2026-08-07	Albers Jeffrey W.	Director	Exercise or conversion	5K	$10.39	$52K	5K
2026-08-03	Turtle Cameron	Chief Executive Officer	Sell	16	$97.46	$2K	568K
2026-08-03	Turtle Cameron	Chief Executive Officer	Sell	1K	$96.82	$135K	568K
2026-08-03	Turtle Cameron	Chief Executive Officer	Sell	6K	$95.93	$541K	569K
2026-08-03	Turtle Cameron	Chief Executive Officer	Sell	7K	$95.10	$681K	575K
2026-08-03	Turtle Cameron	Chief Executive Officer	Sell	800	$93.97	$75K	582K
2026-08-03	Burrows Scott L	Chief Financial Officer	Sell	100	$97.10	$10K	98K
2026-08-03	Burrows Scott L	Chief Financial Officer	Sell	2K	$96.30	$221K	98K
2026-08-03	Burrows Scott L	Chief Financial Officer	Sell	5K	$95.21	$486K	100K
2026-08-03	Burrows Scott L	Chief Financial Officer	Exercise or conversion	8K	$14.50	$109K	105K
2026-07-01	Turtle Cameron	Chief Executive Officer	Sell	590	$88.91	$52K	583K
2026-07-01	Turtle Cameron	Chief Executive Officer	Sell	4K	$88.12	$373K	583K
2026-07-01	Turtle Cameron	Chief Executive Officer	Sell	10K	$87.44	$890K	587K
2026-07-01	Sloan Sheldon	Chief Medical Officer	Sell	2K	$88.34	$162K	0
2026-07-01	Sloan Sheldon	Chief Medical Officer	Sell	7K	$87.52	$569K	2K
2026-07-01	Sloan Sheldon	Chief Medical Officer	Exercise or conversion	8K	$27.46	$229K	8K
2026-07-01	Burrows Scott L	Chief Financial Officer	Sell	2K	$88.37	$152K	98K
2026-07-01	Burrows Scott L	Chief Financial Officer	Sell	6K	$87.55	$506K	100K
2026-07-01	Burrows Scott L	Chief Financial Officer	Exercise or conversion	8K	$14.50	$109K	105K
2026-06-25	Burrows Scott L	Chief Financial Officer	Sell	10K	$87.14	$871K	98K
2026-06-25	Burrows Scott L	Chief Financial Officer	Sell	5K	$87.12	$436K	108K
2026-06-25	Burrows Scott L	Chief Financial Officer	Exercise or conversion	15K	$14.50	$218K	113K
2026-06-23	Fairmount Funds Management LLC	Director	Sell	4.7M	$85.31	$399.7M	0
2026-06-23	Fairmount Funds Management LLC	Director	Conversion	667K	price not stated in the filing	not stated	4.7M
2026-06-22	HENDERSON MICHAEL THOMAS	Director	Sell	20K	$100.00	$2.0M	69K
2026-06-03	Sloan Sheldon	Chief Medical Officer	Sell	8K	$75.00	$625K	0
2026-06-03	Sloan Sheldon	Chief Medical Officer	Exercise or conversion	8K	$27.46	$229K	8K
2026-06-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$71.38	$235K	598K
2026-06-01	Turtle Cameron	Chief Executive Officer	Sell	8K	$70.50	$575K	601K
2026-06-01	Turtle Cameron	Chief Executive Officer	Sell	4K	$69.40	$247K	609K
2026-06-01	Burrows Scott L	Chief Financial Officer	Sell	3K	$72.06	$223K	98K
2026-06-01	Burrows Scott L	Chief Financial Officer	Sell	3K	$70.77	$184K	101K
2026-06-01	Burrows Scott L	Chief Financial Officer	Sell	2K	$69.75	$126K	104K
2026-06-01	Burrows Scott L	Chief Financial Officer	Exercise or conversion	8K	$14.50	$109K	105K
2026-05-08	HENDERSON MICHAEL THOMAS	Director	Sell	19K	$75.35	$1.5M	89K
2026-05-08	HENDERSON MICHAEL THOMAS	Director	Sell	25K	$74.76	$1.9M	108K
2026-05-08	HENDERSON MICHAEL THOMAS	Director	Sell	34K	$73.72	$2.5M	133K
2026-05-08	HENDERSON MICHAEL THOMAS	Director	Sell	2K	$72.57	$174K	166K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	300	$74.96	$22K	613K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	2K	$74.23	$126K	613K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$73.14	$227K	615K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	1K	$71.76	$72K	618K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	4K	$70.77	$255K	619K
2026-05-01	Turtle Cameron	Chief Executive Officer	Sell	5K	$69.54	$369K	622K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	400	$75.37	$30K	0
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	5K	$74.60	$377K	400
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	10K	$73.74	$764K	5K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	13K	$72.94	$932K	16K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	9K	$71.56	$628K	29K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	20K	$70.61	$1.4M	37K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Sell	21K	$69.53	$1.5M	57K
2026-05-01	Sloan Sheldon	Chief Medical Officer	Exercise or conversion	78K	$27.46	$2.2M	78K
2026-05-01	Burrows Scott L	Chief Financial Officer	Sell	13K	$71.37	$892K	98K
2026-05-01	Burrows Scott L	Chief Financial Officer	Exercise or conversion	13K	$14.50	$181K	110K
2026-04-01	Turtle Cameron	Chief Executive Officer	Sell	3K	$49.92	$133K	628K
2026-04-01	Turtle Cameron	Chief Executive Officer	Sell	12K	$49.20	$607K	630K
2026-04-01	Sloan Sheldon	Chief Medical Officer	Sell	8K	$50.00	$398K	0
2026-04-01	Sloan Sheldon	Chief Medical Officer	Exercise or conversion	8K	$21.66	$172K	8K
2026-04-01	Burrows Scott L	Chief Financial Officer	Sell	1K	$49.98	$65K	98K
2026-04-01	Burrows Scott L	Chief Financial Officer	Sell	6K	$49.21	$305K	99K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

19 Form 144 notices on file for SYRE worth $444.9M at the prices reported; 7 in the last 90 days worth $17.7M. Latest: HEIDY KING-JONES filed on 2026-10-01 to sell 29,335 shares ($2.6M) from 2026-10-01.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-10-01	HEIDY KING-JONESOfficer	29K	$2.6M	0.033%	2026-10-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-10-01	CAMERON TURTLEDirector, Officer	45K	$4.0M	0.051%	2026-10-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-09-30	SCOTT BURROWSOfficer	18K	$1.6M	0.020%	2026-09-30	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-09-01	HEIDY KING-JONESOfficer	47K	$4.2M	0.053%	2026-09-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-07	JEFFREY ALBERSDirector	5K	$517K	0.006%	2026-08-07	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-07	SESSIONS, LLCDirector	18K	$1.9M	0.020%	2026-08-07	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-03	SCOTT BURROWSOfficer	30K	$2.9M	0.035%	2026-08-03	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-07-01	CAMERON TURTLEDirector, Officer	45K	$4.0M	0.052%	2026-07-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-25	SCOTT BURROWSOfficer	15K	$1.3M	0.017%	2026-06-25	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-23	Fairmount Healthcare Fund II L.P.Director	4.7M	$399.7M	5.395%	2026-06-23	Goldman Sachs & Co. LLC
2026-06-22	MICHAEL HENDERSONDirector	20K	$1.8M	0.023%	2026-06-22	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-03	SHELDON SLOANOfficer	17K	$1.2M	0.019%	2026-06-03	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-05-08	MICHAEL HENDERSONDirector	80K	$5.8M	0.092%	2026-05-08	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-05-01	SHELDON SLOANOfficer	78K	$5.8M	0.100%	2026-05-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-05-01	SCOTT BURROWSOfficer	28K	$2.0M	0.035%	2026-05-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-04-01	SHELDON SLOANOfficer	8K	$401K	0.010%	2026-04-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-03	SCOTT BURROWSOfficer	10K	$425K	0.013%	2026-03-03	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-02	CAMERON TURTLEDirector, Officer	60K	$2.6M	0.076%	2026-03-02	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-11-03	CAMERON TURTLEDirector, Officer	90K	$2.2M	0.149%	2025-11-03	Morgan Stanley Smith Barney LLC Executive Financial Services

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

10 holders report 5% or more of SYRE in their latest filing, 7 on Schedule 13D (active intent). The largest reported stake is Harwin Peter Evan at 10.0% of the class (10,185,961 shares), filed 2026-10-09 for an event on 2026-10-07.

Filed	Form	Holder	Shares	Of class	Event
2026-10-09	13D/Ano. 8	Harwin Peter Evanindividual	10.2M	10.0%	2026-10-07
2026-10-09	13D/Ano. 8	Kiselak Tomasindividual	10.2M	10.0%	2026-10-07
2026-10-09	13D/Ano. 8	Fairmount Funds Management LLCinvestment adviser	9.4M	9.2%	2026-10-07
2026-10-09	13D/Ano. 8	Fairmount Healthcare Fund II L.P.partnership	9.4M	9.2%	2026-10-07
2026-10-01	13G	Paradigm BioCapital Advisors LPpartnership	4.5M	5.1%	2026-09-24
2026-10-01	13G	Paradigm BioCapital Advisors GP LLCother entity	4.5M	5.1%	2026-09-24
2026-10-01	13G	Senai Asefaw, M.D.individual	4.5M	5.1%	2026-09-24
2026-10-01	13G	Paradigm BioCapital International Fund Ltd.corporation	3.9M	4.5%	2026-09-24
2026-08-14	13G/Ano. 2	RTW Investments, LPinvestment adviser, partnership	4.3M	4.8%	2026-06-30
2026-08-14	13G/Ano. 2	Roderick Wongparent holding company, individual	4.3M	4.8%	2026-06-30
2026-08-14	13G/Ano. 1	Perceptive Advisors LLCinvestment adviser	4.3M	4.9%	2026-06-30
2026-08-14	13G/Ano. 1	Joseph Edelmanindividual	4.3M	4.9%	2026-06-30
2026-08-14	13G/Ano. 1	Perceptive Life Sciences Master Fund, Ltd.corporation	4.3M	4.9%	2026-06-30
2026-06-23	13D/Ano. 7	Peter Evan Harwinindividual	9.7M	10.0%	2026-06-23
2026-06-23	13D/Ano. 7	Tomas Kiselakindividual	9.7M	10.0%	2026-06-23
2026-04-20	13D/Ano. 6	Peter Harwinindividual	9.0M	10.0%	2026-04-16
2026-03-27	13G/Ano. 1	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13
2026-02-17	13G/Ano. 1	KEVIN TANGindividual	1.9M	2.4%	2025-12-31
2026-02-17	13G/Ano. 1	TANG CAPITAL MANAGEMENT, LLCother entity	1.9M	2.4%	2025-12-31
2026-02-17	13G/Ano. 1	TANG CAPITAL PARTNERS, LPpartnership	1.0M	1.3%	2025-12-31
2026-02-17	13G/Ano. 1	TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership	880K	1.1%	2025-12-31
2026-02-17	13G/Ano. 1	TANG CAPITAL PARTNERS IV, INCcorporation	0	0.0%	2025-12-31
2026-02-17	13G/Ano. 1	TANG CAPITAL PARTNERS III, INCcorporation	0	0.0%	2025-12-31

13F holders

Tracked managers holding SYRE at their latest 13F. JSON

5 of the 30 tracked managers held SYRE at their latest 13F, $32.1M in total at quarter-end prices. Millennium Management is the largest at $17.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Millennium Management	2026-06-30	197K	$17.5M	0.01%	+50K
Citadel Advisors	2026-06-30	103K	$9.2M	0.00%	-5K
D. E. Shaw & Co.	2026-06-30	26K	$2.3M	0.00%	new
AQR Capital Management	2026-06-30	23K	$2.0M	0.00%	+2K
Two Sigma Investments	2026-06-30	13K	$1.1M	0.00%	new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In FY 2025 it generated -$169.3M of operating cash flow.

Cash: $162.0M
Equity: $1.10B
Total assets: $1.17B
Shares outstanding: 88,173,762

Quarterly, last 8 quarters

Quarter	Period end	Revenue	Net income	Margin	Diluted EPS
Q2 FY 2026	2026-06-30	n/a	-$36.2M	n/a	n/a
Q1 FY 2026	2026-03-31	n/a	-$69.0M	n/a	-0.74
Q4 FY 2025derived	2025-12-31	n/a	-$62.5M	n/a	n/a
Q3 FY 2025	2025-09-30	n/a	-$11.2M	n/a	n/a
Q2 FY 2025	2025-06-30	n/a	-$36.7M	n/a	n/a
Q1 FY 2025	2025-03-31	n/a	-$44.8M	n/a	n/a
Q4 FY 2024derived	2024-12-31	$0	-$56.3M	n/a	n/a
Q3 FY 2024	2024-09-30	$0	-$69.0M	n/a	1.06

Fiscal years, with buybacks and dividends

Fiscal year	Ends	Revenue	Net income	Operating cash flow	Capex	Buybacks	Dividends
FY 2025	2025-12-31	$0	-$155.2M	-$169.3M	n/a	n/a	n/a
FY 2024	2024-12-31	$0	-$208.0M	-$157.4M	$0	n/a	n/a
FY 2023	2023-12-31	$886K	-$338.8M	-$99.9M	$0	n/a	n/a
FY 2022	2022-12-31	$2.3M	-$83.8M	-$80.1M	$38K	n/a	n/a
FY 2021	2021-12-31	$18.7M	-$65.8M	-$53.7M	$573K	n/a	n/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.

What this page is

Spyre Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Spyre Therapeutics (SYRE), SEC CIK 1636282, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-09.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials: SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
Company record: EDGAR filing index for CIK 1636282Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of SYRE is sold short?

12,505,491 shares were held short at the 2026-10-15 settlement, 7.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is SYRE's daily short volume?

On 2026-10-28, 191,493 of the 288,023 SYRE shares reported to FINRA were sold short, 66.5% of the day's reported volume. Short volume is a flow for one day, not a position.

Does SYRE have fails to deliver?

The SEC's latest file shows 788 SYRE shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.

Are SYRE insiders buying or selling?

Insiders at SYRE reported 42 open-market sells worth $16.9M in the last 90 days and no open-market buys. Latest filing: Turtle Cameron (Chief Executive Officer) on 2026-10-01.

Have SYRE insiders filed to sell?

Who owns 5% or more of SYRE?

What did SYRE report last quarter?

In FY 2025 it generated -$169.3M of operating cash flow.

Which tracked 13F managers own SYRE?

5 of the 30 tracked 13F managers held SYRE shares at their latest filing, $32.1M in all. The largest: Izzy Englander's Millennium Management (197K shares, $17.5M), Ken Griffin's Citadel Advisors (103K shares, $9.2M), D. E. Shaw & Co. (26K shares, $2.3M), Cliff Asness's AQR Capital Management (23K shares, $2.0M), Two Sigma Investments (13K shares, $1.1M).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.